Video

Impact of Disease Staging on Prognosis and Treatment in SCLC

Author(s):

Taofeek K. Owonikoko, MD, PhD,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital

Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Related Content
Lung Cancer | stock.adobe.com
December 20th 2024

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

FDA
December 18th 2024

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
December 17th 2024

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC

NRG1 Fusions in Lung Cancer | Image Credit: © catalin – stock.adobe.com
December 17th 2024

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers